158 related articles for article (PubMed ID: 15206107)
1. Ruthenium anticancer drugs.
Alessio E; Mestroni G; Bergamo A; Sava G
Met Ions Biol Syst; 2004; 42():323-51. PubMed ID: 15206107
[No Abstract] [Full Text] [Related]
2. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
Bergamo A; Sava G
Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium complexes can target determinants of tumour malignancy.
Bergamo A; Sava G
Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
[TBL] [Abstract][Full Text] [Related]
4. Antitumor titanium compounds and related metallocenes.
Caruso F; Rossi M
Met Ions Biol Syst; 2004; 42():353-84. PubMed ID: 15206108
[No Abstract] [Full Text] [Related]
5. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis ES; Emadi A
Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
[No Abstract] [Full Text] [Related]
8. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A.
Chen J; Chen L; Liao S; Zheng K; Ji L
J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393
[TBL] [Abstract][Full Text] [Related]
9. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
10. NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug.
Yuan S; Chen S; Wu H; Jiang H; Zheng S; Zhang Q; Liu Y
Chem Commun (Camb); 2020 Jan; 56(9):1397-1400. PubMed ID: 31912815
[TBL] [Abstract][Full Text] [Related]
11. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
13. Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study.
Besker N; Coletti C; Marrone A; Re N
J Phys Chem B; 2008 Apr; 112(13):3871-5. PubMed ID: 18331025
[TBL] [Abstract][Full Text] [Related]
14. The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins.
Casini A; Temperini C; Gabbiani C; Supuran CT; Messori L
ChemMedChem; 2010 Dec; 5(12):1989-94. PubMed ID: 20931644
[No Abstract] [Full Text] [Related]
15. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
Peacock AF; Sadler PJ
Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
[TBL] [Abstract][Full Text] [Related]
17. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
18. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
Babak MV; Ang WH
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025
[TBL] [Abstract][Full Text] [Related]
19. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
[TBL] [Abstract][Full Text] [Related]
20. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]